Penny Toren - 14 May 2021 Form 4 Insider Report for Vallon Pharmaceuticals, Inc. (GRI)

Reporting relationship: SVP, Regul Affairs & Prog Mgmt
Issuer ticker: GRI
Reported as of: 14 May 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2021, 16:06:16 UTC
Source filing: View source filing
Reporting owner signature: /s/ David Baker, attorney-in-fact

Key filing fact

Penny Toren filed Form 4 for Vallon Pharmaceuticals, Inc. (GRI) on 18 May 2021.

Key facts

This page summarizes Penny Toren's Form 4 filing for Vallon Pharmaceuticals, Inc. (GRI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 May 2021, 16:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 14 May 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $3.66
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Vests as to 25% of the underlying shares of common stock on the first annual anniversary of the date of grant, then in 12 equal quarterly installments such that the stock option is fully vested on the fourth annual anniversary of the date of grant.